Long-term outcome after perioperative chemotherapy and surgery for gastro-esophageal adenocarcinoma
Background: The long-term fate of patients treated for resectable gastro-esophageal adenocarcinoma with perioperative chemotherapy outside randomized clinical trials (RCTs) is poorly described. In this national cohort, we report on outcomes after 12 years. Materials and methods: Baseline clinicopath...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-06-01
|
| Series: | ESMO Gastrointestinal Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2949819825000524 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849689647715713024 |
|---|---|
| author | S. Shim A.C. Larsen L. Bæksgaard P. Pfeiffer M. Nordsmark J.R. Sørensen A.K. Motavaf M. Ladekarl |
| author_facet | S. Shim A.C. Larsen L. Bæksgaard P. Pfeiffer M. Nordsmark J.R. Sørensen A.K. Motavaf M. Ladekarl |
| author_sort | S. Shim |
| collection | DOAJ |
| description | Background: The long-term fate of patients treated for resectable gastro-esophageal adenocarcinoma with perioperative chemotherapy outside randomized clinical trials (RCTs) is poorly described. In this national cohort, we report on outcomes after 12 years. Materials and methods: Baseline clinicopathological factors and blood tests were collected in 285 patients treated from May 2008 to June 2010, and postsurgical factors were collected in the 202 patients that were radically resected. Response to preoperative chemotherapy was assessed by postsurgical restaging. Additional information on second cancers, comorbidities, and competing causes of death was obtained. Results: Overall survival (OS) at 5 and 10 years was 31.9% and 24.2%, respectively. Multivariate analysis (MA) showed prognostic value of clinical T- and N-stage, dysphagia, and Charlson Comorbidity Index. Elevated leucocytes and lactate dehydrogenase, and low lymphocytes were additional adverse prognostic factors. Ten-year incidence rate of second cancers was 10.1%.OS at 5 and 10 years from radical surgery was 43.1% and 32.1%, respectively. MA showed prognostic value of postneoadjuvant pathological (yp) Union for International Cancer Control (UICC) stage and downstaging. However, downstaging was strongly correlated with clinical stage. At the 5-year landmark, marginally significant trends toward a favorable recurrence-free survival were associated with ypT0 and age <70 years, but only 3.4% experienced late recurrences. Postoperative complications caused a quarter of deaths in the half of radically resected patients who died without recurrence. Conclusions: Five-year OS was 4%-6% points inferior to RCTs. Pretreatment white blood cell counts, but not postoperative, could supplement clinical prognostic factors. Downstaging by preoperative chemotherapy was prognostic but correlated strongly with pretreatment clinical stage. |
| format | Article |
| id | doaj-art-11eef02f6b574e949e8d418118fa961e |
| institution | DOAJ |
| issn | 2949-8198 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | ESMO Gastrointestinal Oncology |
| spelling | doaj-art-11eef02f6b574e949e8d418118fa961e2025-08-20T03:21:32ZengElsevierESMO Gastrointestinal Oncology2949-81982025-06-01810018310.1016/j.esmogo.2025.100183Long-term outcome after perioperative chemotherapy and surgery for gastro-esophageal adenocarcinomaS. Shim0A.C. Larsen1L. Bæksgaard2P. Pfeiffer3M. Nordsmark4J.R. Sørensen5A.K. Motavaf6M. Ladekarl7Department of Oncology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark; Department of Clinical Medicine, Aalborg University Hospital, Aalborg, DenmarkDepartment of Clinical Medicine, Aalborg University Hospital, Aalborg, Denmark; Department of Abdominal Surgery, Aalborg University Hospital, Aalborg, DenmarkDepartment of Oncology, Rigshospitalet, Copenhagen, DenmarkDepartment of Oncology, Odense University Hospital, Odense, Denmark; University of Southern Denmark, Odense, DenmarkDepartment of Oncology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, DenmarkCenter for Clinical Data Science (CLINDA), Aalborg University and Aalborg University Hospital, Aalborg, DenmarkDepartment of Oncology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, DenmarkDepartment of Oncology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark; Department of Clinical Medicine, Aalborg University Hospital, Aalborg, Denmark; Correspondence to: Prof. Morten Ladekarl, Department of Oncology, Aalborg University Hospital, Hobrovej 22, 9000 Aalborg, Denmark. Tel: +456139-9326Background: The long-term fate of patients treated for resectable gastro-esophageal adenocarcinoma with perioperative chemotherapy outside randomized clinical trials (RCTs) is poorly described. In this national cohort, we report on outcomes after 12 years. Materials and methods: Baseline clinicopathological factors and blood tests were collected in 285 patients treated from May 2008 to June 2010, and postsurgical factors were collected in the 202 patients that were radically resected. Response to preoperative chemotherapy was assessed by postsurgical restaging. Additional information on second cancers, comorbidities, and competing causes of death was obtained. Results: Overall survival (OS) at 5 and 10 years was 31.9% and 24.2%, respectively. Multivariate analysis (MA) showed prognostic value of clinical T- and N-stage, dysphagia, and Charlson Comorbidity Index. Elevated leucocytes and lactate dehydrogenase, and low lymphocytes were additional adverse prognostic factors. Ten-year incidence rate of second cancers was 10.1%.OS at 5 and 10 years from radical surgery was 43.1% and 32.1%, respectively. MA showed prognostic value of postneoadjuvant pathological (yp) Union for International Cancer Control (UICC) stage and downstaging. However, downstaging was strongly correlated with clinical stage. At the 5-year landmark, marginally significant trends toward a favorable recurrence-free survival were associated with ypT0 and age <70 years, but only 3.4% experienced late recurrences. Postoperative complications caused a quarter of deaths in the half of radically resected patients who died without recurrence. Conclusions: Five-year OS was 4%-6% points inferior to RCTs. Pretreatment white blood cell counts, but not postoperative, could supplement clinical prognostic factors. Downstaging by preoperative chemotherapy was prognostic but correlated strongly with pretreatment clinical stage.http://www.sciencedirect.com/science/article/pii/S2949819825000524esophago-gastric adenocarcinomalymphocytesperioperative chemotherapynational cohort studyrestaging |
| spellingShingle | S. Shim A.C. Larsen L. Bæksgaard P. Pfeiffer M. Nordsmark J.R. Sørensen A.K. Motavaf M. Ladekarl Long-term outcome after perioperative chemotherapy and surgery for gastro-esophageal adenocarcinoma ESMO Gastrointestinal Oncology esophago-gastric adenocarcinoma lymphocytes perioperative chemotherapy national cohort study restaging |
| title | Long-term outcome after perioperative chemotherapy and surgery for gastro-esophageal adenocarcinoma |
| title_full | Long-term outcome after perioperative chemotherapy and surgery for gastro-esophageal adenocarcinoma |
| title_fullStr | Long-term outcome after perioperative chemotherapy and surgery for gastro-esophageal adenocarcinoma |
| title_full_unstemmed | Long-term outcome after perioperative chemotherapy and surgery for gastro-esophageal adenocarcinoma |
| title_short | Long-term outcome after perioperative chemotherapy and surgery for gastro-esophageal adenocarcinoma |
| title_sort | long term outcome after perioperative chemotherapy and surgery for gastro esophageal adenocarcinoma |
| topic | esophago-gastric adenocarcinoma lymphocytes perioperative chemotherapy national cohort study restaging |
| url | http://www.sciencedirect.com/science/article/pii/S2949819825000524 |
| work_keys_str_mv | AT sshim longtermoutcomeafterperioperativechemotherapyandsurgeryforgastroesophagealadenocarcinoma AT aclarsen longtermoutcomeafterperioperativechemotherapyandsurgeryforgastroesophagealadenocarcinoma AT lbæksgaard longtermoutcomeafterperioperativechemotherapyandsurgeryforgastroesophagealadenocarcinoma AT ppfeiffer longtermoutcomeafterperioperativechemotherapyandsurgeryforgastroesophagealadenocarcinoma AT mnordsmark longtermoutcomeafterperioperativechemotherapyandsurgeryforgastroesophagealadenocarcinoma AT jrsørensen longtermoutcomeafterperioperativechemotherapyandsurgeryforgastroesophagealadenocarcinoma AT akmotavaf longtermoutcomeafterperioperativechemotherapyandsurgeryforgastroesophagealadenocarcinoma AT mladekarl longtermoutcomeafterperioperativechemotherapyandsurgeryforgastroesophagealadenocarcinoma |